Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025

1. FollowUs:
Genome Editing Market Industry Size , Share, Trends, Revenue Growth
And Forecast To 2024| Grand View Research, Inc
The global genome editing market is anticipated to reach USD 8.1 billion by 2025, according to a new report by
Grand View Research, Inc. Key drivers attributing to the expansion include early applications of DNA editing to
therapeutics. Use of the technology for the disease eradication through direct correction of disturbances in
normal physiology, engineering the immune response, and alteration of pathogen targets in the host is
anticipated to drive the market with substantial opportunities.
The ability of genome editing therapies to offer a significant improvement over current treatment options is
important in enabling editing technologies to capture significant revenue share. Improved efficacy, reduced
side effects, and the potential for cure for specific diseases, can be attributed to induce growth i n the coming
years.
Moreover, technological advancements with respect to the development of novel vectors for delivery is
anticipated to fuel growth in the coming years. Rising competition amongst the operating entities in order to
gain the larger share of revenue is also responsible for the projected growth. These companies leverage
industry collaborations for the acceleration of diversified product pipelines.
Browse Details of Report @ www.grandviewresearch.com/industry-analysis/genome-editing-market
“The global genome editing market size was valued at USD 2.25 billion in
2015.”

2. FollowUs:
Further Key Findings from the Report Suggest:
 There has beengreat excitementsurrounding the highlyadaptable CRISPR technology.
 The increased ease of retargeting and the abilityto multiplex goesa long way toward explainingthe speed
with which CRISPR-centric companies have sprung up.
 Ex-vivomode of deliveryaccounted for the largest share of the revenue.
 Therapy through ex-vivomode of deliveryallow the control over the specificdosage of therapeutic molecules
deliveredto cells.
 Cell line engineeringdominatedwith respect to revenue generationowing to the high utilizationof
technology in stem cell engineering.
 There is comparatively, higher adoption of the technology in the biotechnologyand pharmaceutical
organizations for the purpose of therapeutic development.
 Availabilityof other servicessuch as gRNA library production and screening service along with editingis
anticipated to propel growth in the outsourcing services.
 Asia Pacific is anticipated to witnessfastest growth over the forecast period owing to rising penetration of
technology in comparatively immature market.
 Key players contributing in this market are Thermo Fisher Scientific,Inc., Sangamo, Editas Medicine,
Recombinetics,Inc, Sigma Aldrich Corporation, CRISPR THERAPEUTICS, IntelliaTherapeutics, Inc., Caribou
Biosciences,Inc.
 These participants are capitalizing on unique advantages offeredby the nuclease technology,they are working
on.
Grand ViewResearch has segmentedthe molecular scissors/genome editingmarket on the basis of technology,
deliverymethod,application, end-use,service,and region:
Molecular Scissors/Genome Editing Technology Outlook (Revenue, USD Million, 2014 - 2025)
 (CRISPR)/Cas9
 TALENs/MegaTALs
 ZFN
 Others
Molecular Scissors/Genome Editing Delivery Method Outlook (Revenue,USD Million, 2014 - 2025)
 Ex-Vivo
 In-Vivo
Molecular Scissors/Genome Editing Application Outlook (Revenue, USD Million, 2014 - 2025)
 Cell Line Engineering
 Animal Genetic Engineering
 Plant Genetic Engineering
 Other Applications

3. FollowUs:
Molecular Scissors/Genome Editing End-use Outlook (Revenue, USD Million, 2014 - 2025)
 Biotechnology& Pharmaceutical Companies
 Academic & Government Research Institutes
 Contract Research Organizations
Molecular Scissors/Genome Editing Service Outlook (Revenue, USD Million,2014 - 2025)
 Contract
 In-house
Molecular Scissors/Genome Editing Service Outlook (Revenue, USD Million,2014 - 2025)
 North America
o U.S.
o Canada
 Europe
o Germany
o UK
 Asia Pacific
o Japan
o China
 Latin America
o Brazil
 Middle East and Africa (MEA)
o South Africa
Browse Related Category Reports @ www.grandviewresearch.com/industry/biotechnology
Table of Content of Genome Editing Market
Chapter 1 ResearchMethodology
1.1 InformationProcurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 Genome EditingMarketVariables,Trends & Scope
3.1 Market Segmentation&Scope
3.1.1 Market DriverAnalysis
3.1.1.1 Successinpre-clinical modelsdrivesdemandsforgenome editingtherapeutics
3.1.1.2 Risingcompetitionamongstmarketparticipantsforbusinessdevelopment

4. FollowUs:
3.1.1.3 Easy editingsolutionsfordevelopmentof therapeuticsforbroadrange of diseases
3.1.1.4 Increasingdemandforsyntheticgenesandgeneticallymodifiedorganisms
3.1.1.5 Technological advancementsingene editingtechnologies
3.1.1.6 Risingadoption inagricultural biotechnology
3.1.2 Market RestraintAnalysis
3.1.2.1 Challengeswithrespecttoclinical translation
3.1.2.2 Regulatory,scientific,andethical challengespertainingtothe use of gene modifiedproducts
3.1.2.3 Off-targeteffectsof CRISPRtechnology
3.2 Penetration&GrowthProspectMappingforTechnology,2015
3.3 Molecularscissors/genome editing -SwotAnalysis, ByFactor(Political &Legal,EconomicAnd
Technological)
3.4 IndustryAnalysis - Porter’s
3.5 MolecularScissors/Genome EditingTechnologies:Pipeline Analysis
3.5.1 Sangamo
3.5.2 Cellectis
3.5.3 Calyxt
3.5.4 bluebirdbio
3.5.5 Editas Medicine
3.5.6 IntelliaTherapeutics,Inc.
3.5.7 CRISPRTHERAPEUTICS
3.5.8 PrecisionBiosciences
3.5.9 PrecisionBiosciences(Nonmedical domain)
3.5.10 CaribouBiosciences
3.5.11 Cibus
3.5.12 Recombinetics,Inc
3.6 Intellectual Property
3.7 RegulatoryIssues
3.7.1 Orphan diseases
3.7.2 Germline editing
3.7.3 Safetyissues
Chapter 4 Genome EditingMarket:TechnologyEstimates & Trend Analysis
4.1 MolecularScissors/Genome EditingMarket:TechnologyMovementAnalysis

5. FollowUs:
4.2 MolecularScissors/Genome EditingTechnologyComparison
4.3 (CRISPR)/Cas9
4.3.1 Global (CRISPR)/Cas9market,2014 - 2025 (USDMillion)
4.4 TALENs/MegaTALs
4.4.1 Global TALENs/MegaTALsmarket,2014 - 2025 (USD Million)
4.5 ZFN
4.5.1 Global ZFN market,2014 - 2025 (USD Million)
4.6 OtherTechnologies
4.6.1 Global othertechnologiesmarket,2014 - 2025 (USD Million)
Chapter 5 Genome EditingMarket:DeliveryMethodEstimates & Trend Analysis
5.1 MolecularScissors/Genome EditingMarket:DeliveryMethodMovementAnalysis
5.1.1 Comparisonof DeliveryMethods
5.1.1.1 Viral delivery
5.1.1.1.1 AAV (AdenoAssociatedVirus).
5.1.1.1.2 IDLV (Integrase DeficientLentivirus).
5.1.1.2 Non-viral delivery
5.1.1.2.1 LipidMediated
5.1.1.2.2 Electroporation
5.2 Ex-vivo
5.2.1 Global ex-vivodeliverymarket,2014 - 2025 (USD Million)
5.3 In-vivo
5.3.1 Global in-vivodeliverymarket,2014 - 2025 (USD Million)
Chapter 6 Genome EditingMarket:ApplicationEstimates & Trend Analysis
6.1 MolecularScissors/Genome EditingMarket:ApplicationMovementAnalysis
6.2 Cell Line Engineering
6.2.1 Global cell line engineeringmarket,2014 - 2025 (USD Million)
6.3 Animal GeneticEngineering
6.3.1 Global animal geneticengineeringmarket,2014 - 2025 (USD Million)
6.4 PlantGeneticEngineering
6.4.1 Global plantgeneticengineeringmarket,2014 - 2025 (USD Million)
6.5 Others
6.5.1 Global otherapplicationsmarket,2014 - 2025 (USD Million)

6. FollowUs:
Chapter 7 Genome EditingMarket:End-use Estimates & Trend Analysis
7.1 MolecularScissors/Genome EditingMarket:End-use MovementAnalysis
7.2 Biotechnology&Pharmaceutical Companies
7.2.1 Global biotechnology&pharmaceutical companiesmarket,2014 - 2025 (USD Million)
7.3 Academic& GovernmentResearchInstitutes
7.3.1 Global academic& governmentresearchinstitutesmarket,2014 - 2025 (USD Million)
7.4 Contract ResearchOrganizations(CROs)
7.4.1 Global CROs market,2014 - 2025 (USD Million)
Chapter 8 Genome EditingMarket:Service Estimates & Trend Analysis
8.1 Molecularscissors/genome editingMarket:Service MovementAnalysis
8.2 In-house
8.2.1 Global in-house gene editingmarket,2014 - 2025 (USD Million)
8.3 Contract
8.3.1 Global contract gene editingservicesmarket,2014 - 2025 (USD Million)
Chapter 9 Genome EditingMarket:Regional Estimates & Trend Analysis,by Technology,DeliveryMethod,
Application,End-use,& Service
9.1 MolecularScissors/Genome EditingMarketShare By Region,2015 & 2025
9.2 NorthAmerica
9.2.1 North Americamolecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.2.2 U.S.
9.2.2.1 U.S molecularscissors/ genome editingculture market,2014 - 2025 (USD Million)
9.2.3 Canada
9.2.3.1 Canadamolecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.3 Europe
9.3.1 Europe molecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.3.2 Germany
9.3.2.1 Germanymolecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.3.3 UK
9.3.3.1 UK molecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.4 AsiaPacific
9.4.1 AsiaPacificmolecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.4.2 Japan

7. FollowUs:
9.4.2.1 Japanmolecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.4.3 China
9.4.3.1 Chinamolecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.5 LatinAmerica
9.5.1 Latin Americamolecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.5.2 Brazil
9.5.2.1 Brazil molecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.6 Middle East& Africa
9.6.1 Middle East & Africamolecularscissors/genome editingmarket,2014 - 2025 (USD Million)
9.6.2 South Africa
9.6.2.1 SouthAfricamolecularscissors/genome editingmarket,2014 - 2025 (USD Million)
Chapter 10 Competitive Landscape
10.1 StrategyFramework
10.1.1 Genome editingcompaniesare developingproductsinarange of markets
10.1.2 Genome EditingCompaniesare targetingavarietyof marketsof varioussizes
10.2 Market ParticipationCategorization
10.3 CompanyProfiles
10.3.1 Merck KGaA
10.3.1.1 Companyoverview
10.3.1.1.1 Sigma-AldrichCo.LLC
10.3.1.2 Financial performance
10.3.1.2.1 Financial performance
10.3.1.3 Product benchmarking
10.3.1.4 Strategicinitiatives
10.3.2 Cibus
10.3.2.1 Companyoverview
10.3.2.1.1 Nucelis
10.3.2.2 Financial performance
10.3.2.2.1 Financial performance
10.3.2.3 Product benchmarking
10.3.2.4 Strategicinitiatives
10.3.3 Recombinetics,Inc

8. FollowUs:
10.3.3.1 Companyoverview
10.3.3.2 Financial performance
10.3.3.3 Product benchmarking
10.3.3.4 Strategicinitiatives
10.3.4 Sangamo
10.3.4.1 Companyoverview
10.3.4.2 Financial performance
10.3.4.3 Product benchmarking
10.3.4.4 Strategicinitiatives
10.3.5 EditasMedicine
10.3.5.1 Companyoverview
10.3.5.2 Financial performance
10.3.5.3 Product benchmarking
10.3.5.4 Strategicinitiatives
10.3.6 PrecisionBiosciences
10.3.6.1 Companyoverview
10.3.6.2 Financial performance
10.3.6.3 Product benchmarking
10.3.6.4 Strategicinitiatives
10.3.7 CRISPRTHERAPEUTICS
10.3.7.1 Companyoverview
10.3.7.2 Financial performance
10.3.7.3 Product benchmarking
10.3.7.4 Strategicinitiatives
10.3.8 IntelliaTherapeutics,Inc.
10.3.8.1 Companyoverview
10.3.8.2 Financial performance
10.3.8.3 Product benchmarking
10.3.8.4 Strategicinitiatives
10.3.9 CaribouBiosciences,Inc
10.3.9.1 Companyoverview
10.3.9.2 Financial performance

9. FollowUs:
10.3.9.3 Product benchmarking
10.3.9.4 Strategicinitiatives
10.3.10 Cellectis
10.3.10.1 Companyoverview
10.3.10.1.1 Calyxt
10.3.10.2 Financial performance
10.3.10.2.1 Financial performance (Calyxt)
10.3.10.3 Productbenchmarking
10.3.10.4 Strategicinitiatives
10.3.11 AstraZeneca
10.3.11.1 Companyoverview
10.3.11.2 Financial performance
10.3.11.3 Productbenchmarking
10.3.11.4 Strategicinitiatives
10.3.12 Takara BioUSA
10.3.12.1 Companyoverview
10.3.12.2 Financial performance
10.3.12.3 Productbenchmarking
10.3.12.4 Strategicinitiatives
10.3.13 HorizonDiscoveryGroupplc
10.3.13.1 Companyoverview
10.3.13.2 Financial performance
10.3.13.3 Productbenchmarking
10.3.13.4 Strategicinitiatives
10.3.14 IntegratedDNA Technologies,Inc.
10.3.14.1 Companyoverview
10.3.14.2 Financial performance
10.3.14.3 Productbenchmarking
10.3.15 EgenesisInc.
10.3.15.1 Companyoverview
10.3.15.2 Financial performance
10.3.15.3 Productbenchmarking

10. FollowUs:
10.3.16 GenScript
10.3.16.1 Companyoverview
10.3.16.2 Financial performance
10.3.16.3 Productbenchmarking
10.3.16.4 Strategicinitiatives
10.3.17 NewEnglandBiolabs
10.3.17.1 Companyoverview
10.3.17.2 Financial performance
10.3.17.3 Productbenchmarking
10.3.17.4 Strategicinitiatives
10.3.18 OriGene Technologies,Inc.
10.3.18.1 Companyoverview
10.3.18.2 Financial performance
10.3.18.3 Productbenchmarking
10.3.18.4 Strategicinitiatives
10.3.19 bluebirdbio,Inc.
10.3.19.1 Companyoverview
10.3.19.1.1 PrecisionGenome Engineering,Inc.(Pregenen)
10.3.19.2 Financial performance
10.3.19.2.1 Financial performance
10.3.19.3 Productbenchmarking
10.3.19.4 Strategicinitiatives
10.3.20 Lonza
10.3.20.1 Companyoverview
10.3.20.2 Financial performance
10.3.20.3 Productbenchmarking
10.3.20.4 Strategicinitiatives
10.3.21 ThermoFisherScientific,Inc.
10.3.21.1 Companyoverview
10.3.21.2 Financial performance
10.3.21.3 Productbenchmarking
10.3.21.4 Strategicinitiatives

11. FollowUs:
About Us:
Grand ViewResearch, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To helpclients make informed business decisions, the company offers
market intelligence studiesensuring relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist,USA
Grand ViewResearch, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: http://www.grandviewresearch.com

12. FollowUs: